By combining CAR T cell therapy with oncolytic vaccinia virus and TGF-β blockade, we observed significantly improved T cell infiltration at both primary and metastatic tumour sites, leading to enhanced tumour suppression, significantly improved overall survival and a marked reduction in metastatic burden. The gene discussed is TGFB1; the disease is neoplasm.